Gain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access 

Built with biopharmaceutical industry insights, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is designed to showcase how technical advancements can be leveraged to support novel pipeline progression, making earlier therapeutic interventions possible for improved patient outcomes. 

Arriving at an important time following the FDA’s recent ctDNA draft guidance, this forum will unite a community of precision oncology trailblazers to debate how we can accelerate the application of non-invasive testing for early-stage drug development use and provide deeper insights into tumor biology and prognosis. 

Tailored to showcase latest innovations, leading opinions, assay validation strategies and novel trial designs, join this exclusive community to engage in discussions on the critical bottlenecks within MRD, molecular response, screening and early detection assays to support their clinical utility and place in routine cancer care.  

What’s more, this summit is available to biopharma, academia and those who work in hospitals for FREE – So you can be at the forefront of liquid biopsy progress in earlier settings this November. 

5 Key Reasons to Attend


Update your understanding of rapidly evolving ctDNA screening & MRD LBx applications with KOL perspectives, including Gary Keloff, NCI & Zeng Feng, EMD Serono 

translate assay

Translate assay advancements into streamlined stratification strategies through greater ctDNA assay clarity, with MRD trial updates from Aadel Chaudhuri, Washington University School of Medicine 


Overcome logistical and technical challenges limiting ctDNA’s utility for treatment selection & screening to access shorter trial timelines with Arnab Basu, O’Neal Comprehensive Cancer Center 

gain future

Gain future thinking perspectives on the importance of industry-wide understanding across assay sensitivity and specificity for informed LBx-based treatment decision making with BMS & EMD Serono 

navigate reg

Navigate regulatory guidance to pave a future for LBx-based clinical endpoints supported by analytically validated ctDNA monitoring assays with Gritstone bio